Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

24 Jun 2015

Abstract excerpt

T cell prolymphocytic leukemia (T-PLL) is a rare, mature T cell neoplasm with distinct features and an aggressive clinical course. Early relapse and short overall survival are commonplace. Use of the monoclonal anti-CD52 antibody alemtuzumab has improved the rate of complete remission and duration of response to more than 50% and between 6 and 12 months, respectively. Despite this advance, without an allogeneic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine and Purinergic Signaling
Share to Chronic Lymphocytic Leukemia Research
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26109102
DOI: 10.1126/scitranslmed.aaa5079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemiaPMID 26109102Read ↗

T-Cell Prolymphocytic Leukemia: Diagnosis, Pathogenesis, and Treatment.Semantic proximity Read ↗

Optimizing drug combinations for T-PLL: restoring DNA damage and P53-mediated apoptotic responsesSemantic proximity Read ↗

Targeting epigenetic regulators in the treatment of T-cell lymphoma.Semantic proximity Read ↗

Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity Read ↗

Management of prolymphocytic leukemia.Semantic proximity Read ↗

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.Semantic proximity Read ↗

Immunophenotypic Characterization of T-Cell Prolymphocytic LeukemiaSemantic proximity Read ↗

Epigenetic Modulation with Histone Deacetylase Inhibitors in Combination with ImmunotherapySemantic proximity Read ↗

Dual STAT3/STAT5 inhibition as a novel treatment strategy in T-prolymphocytic leukemia.Semantic proximity Read ↗

PROTACs: Promising Approaches for Epigenetic Strategies to Overcome Drug ResistanceSemantic proximity Read ↗

T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.Semantic proximity Read ↗

Romidepsin in peripheral and cutaneous T‐cell lymphoma: mechanistic implications from clinical and correlative dataSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.